Table 1.

Patient characteristics and clinicopathological variables of the study cohort based on national cancer quality registry data.

	All samples	ER+/HER2−/LN+	ER+/HER2−/LN−	HER2+/ER+	HER2+/ER−	TNBC
Number of samples	3520	943	1527	321	140	340
ER status (%)
Negative (ER IHC ≤ 10%)*	14.5	0	0	0	100	100
Positive (ER IHC > 10%)*	84.2	100	100	100	0	0
NA	1.3	0	0	0	0	0
PR status (%)
Negative (PR IHC ≤ 10%)*	26.5	13	12	32	96	100
Positive (PR IHC > 10%)*	72.1	87	88	68	4	0
NA	1.4	0	0	0	0	0
HER2 status (%)
Negative	82.4	100	100	0	0	100
Positive	13.2	0	0	100	100	0
NA	4.4	0	0	0	0	0
Age (median and range)	65 (25–100)	65 (25–95)	65 (30–100)	63 (30–95)	70 (35–95)	65 (30–95)
Tumor size (median mm and range)	17 (0–126)	20 (0–126)	15 (1–110)	18 (1–120)	20.5 (0–70)	20 (0–100)
NHG (%)
1	15	13	24	2	0	1
2	47	56	55	30	11	11
3	36	30	20	66	84	84
NA	2	2	1	3	4	3
Lymph node status (%)
0 positive nodes	59	0	100	54	43	64
1–3 positive nodes	27	71	0	27	31	24
≥4 positive nodes	9	23	0	12	19	8
Sub micro metastasis	2	6	0	3	2	2
NA	3	0	0	4	6	2
Treatment (%)	All samples	ER+/HER2−/LN+	ER+/HER2−/LN−	HER2+/ER+	HER2+/ER−	TNBC
Endocrine only	49	48	71	17	1	1
ACT only	8	1	0	0	1	70
Endocrine & ACT	22	49	15	2.5	0	1
Anti-HER2 & ACT	3	0	0	2	79	1
Anti-HER2 & ACT & endocrine	8	0.7	0	74	6	0
Untreated	10	1.6	13	3	8	24
NA or other combination	0	0	1	1.5	5	3

*In Sweden the cut-off by IHC for ER and PR is ≤10% staining intensity.

NHG: Nottingham grade index.

ACT: Adjuvant chemotherapy.

Anti-HER2: HER2-targeted therapy (mainly trastuzumab).

NA: data not available.

Bold groups indicate clinical treatment groups used for signature evaluation.